OSRH, OSRHW · CIK 0001840425 · operating
A healthcare holding company headquartered in Bellevue, Washington, OSR Holdings develops immunotherapy candidates and biologics-based medical solutions. The company's immunotherapy pipeline includes VXM01, a glioblastoma candidate in phase 2 clinical development, alongside several preclinical-stage programs targeting various cancer antigens including mesothelin, WT1, CEA, and PD-L1. The company also develops design-augmented biologics, with DRT-102 in clinical-stage development for spinal fusion applications and DRT-101 at the preclinical stage for osteoarthritis treatment.
Beyond product development, OSR Holdings distributes neurovascular intervention medical devices and systems. The company maintains a small operational footprint with 19 full-time employees and operates across the United States, Switzerland, and South Korea. As a Delaware-incorporated company trading on Nasdaq, OSR Holdings operates across multiple therapeutic areas spanning oncology, orthopedics, and neurovascular intervention.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.54 | $-0.54 | -1180.0% | |
| 2023 | $0.05 | $0.05 | — | |
| 2022 | — | — | — |